Kenvue Inc. (NYSE:KVUE) Shares Sold by Yacktman Asset Management LP

Yacktman Asset Management LP trimmed its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 0.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,270,488 shares of the company's stock after selling 36,184 shares during the quarter. Kenvue makes up approximately 2.6% of Yacktman Asset Management LP's investment portfolio, making the stock its 15th largest position. Yacktman Asset Management LP owned approximately 0.43% of Kenvue worth $198,326,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. AlphaStar Capital Management LLC increased its stake in Kenvue by 3.4% during the first quarter. AlphaStar Capital Management LLC now owns 23,586 shares of the company's stock worth $566,000 after acquiring an additional 781 shares during the last quarter. M&T Bank Corp grew its stake in shares of Kenvue by 11.9% in the first quarter. M&T Bank Corp now owns 118,131 shares of the company's stock valued at $2,832,000 after buying an additional 12,584 shares in the last quarter. Stratos Wealth Partners LTD. grew its stake in Kenvue by 10.4% during the 1st quarter. Stratos Wealth Partners LTD. now owns 14,857 shares of the company's stock worth $356,000 after purchasing an additional 1,396 shares in the last quarter. 49 Wealth Management LLC acquired a new position in Kenvue during the 1st quarter worth $407,000. Finally, Beverly Hills Private Wealth LLC grew its stake in Kenvue by 4.4% during the 1st quarter. Beverly Hills Private Wealth LLC now owns 19,254 shares of the company's stock worth $462,000 after purchasing an additional 817 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Trading Up 0.1%

Shares of KVUE traded up $0.03 during trading hours on Wednesday, hitting $20.73. The stock had a trading volume of 15,930,192 shares, compared to its average volume of 16,126,555. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 0.86. The firm has a market cap of $39.77 billion, a P/E ratio of 37.69, a P/E/G ratio of 3.25 and a beta of 0.83. The company's fifty day simple moving average is $22.51 and its 200 day simple moving average is $22.31. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The company had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. During the same period last year, the company posted $0.28 earnings per share. The firm's revenue was down 3.9% compared to the same quarter last year. Equities research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th were given a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.96%. The ex-dividend date was Wednesday, May 14th. Kenvue's dividend payout ratio (DPR) is presently 149.09%.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. UBS Group boosted their target price on Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Friday, May 9th. Redburn Atlantic began coverage on Kenvue in a research report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price target on the stock. Evercore ISI began coverage on Kenvue in a research report on Monday, March 24th. They issued an "in-line" rating and a $25.00 price target on the stock. Barclays boosted their price target on Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research report on Monday, May 12th. Finally, Citigroup restated a "neutral" rating on shares of Kenvue in a research report on Friday, June 13th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Kenvue has a consensus rating of "Hold" and a consensus target price of $25.33.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.